πŸ‡ΊπŸ‡Έ FDA
Patent

US 12351644

Anti-CD73 antibodies

granted A61KA61K2039/505A61P

Quick answer

US patent 12351644 (Anti-CD73 antibodies) held by Corvus Pharmaceuticals, Inc. expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corvus Pharmaceuticals, Inc.
Grant date
Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61P, A61P35/00